CINECA IRIS Institutional Research Information System

SAGLIO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.130
EU - Europa 13.720
AS - Asia 7.385
AF - Africa 140
SA - Sud America 108
OC - Oceania 83
Continente sconosciuto - Info sul continente non disponibili 21
Totale 40.587
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.823
CN - Cina 4.129
IT - Italia 2.889
IE - Irlanda 2.056
SE - Svezia 1.525
DE - Germania 1.440
UA - Ucraina 1.347
FR - Francia 1.242
SG - Singapore 1.076
FI - Finlandia 972
KR - Corea 814
GB - Regno Unito 520
VN - Vietnam 435
PL - Polonia 425
DK - Danimarca 353
AT - Austria 326
JP - Giappone 278
CA - Canada 266
IN - India 220
HK - Hong Kong 108
BE - Belgio 103
NL - Olanda 88
ES - Italia 74
AU - Australia 73
IR - Iran 55
TR - Turchia 52
RO - Romania 51
RU - Federazione Russa 50
GR - Grecia 49
SN - Senegal 46
BR - Brasile 44
CZ - Repubblica Ceca 44
CH - Svizzera 41
LB - Libano 36
PT - Portogallo 32
TW - Taiwan 32
MX - Messico 30
PK - Pakistan 25
IL - Israele 23
EG - Egitto 22
MU - Mauritius 22
NO - Norvegia 22
AR - Argentina 20
MY - Malesia 20
EU - Europa 18
CL - Cile 16
CO - Colombia 15
UZ - Uzbekistan 14
BG - Bulgaria 13
ZA - Sudafrica 13
IQ - Iraq 12
NG - Nigeria 12
ID - Indonesia 10
NZ - Nuova Zelanda 10
TH - Thailandia 9
HR - Croazia 8
HU - Ungheria 8
PH - Filippine 8
SA - Arabia Saudita 8
SI - Slovenia 8
LU - Lussemburgo 7
PR - Porto Rico 6
SK - Slovacchia (Repubblica Slovacca) 6
JO - Giordania 5
PE - Perù 5
CI - Costa d'Avorio 4
KE - Kenya 4
MA - Marocco 4
RS - Serbia 4
TN - Tunisia 4
UY - Uruguay 4
AP - ???statistics.table.value.countryCode.AP??? 3
AZ - Azerbaigian 3
CR - Costa Rica 3
DZ - Algeria 3
MK - Macedonia 3
MT - Malta 3
TZ - Tanzania 3
BD - Bangladesh 2
BO - Bolivia 2
BT - Bhutan 2
BY - Bielorussia 2
ET - Etiopia 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LT - Lituania 2
LV - Lettonia 2
MO - Macao, regione amministrativa speciale della Cina 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
GT - Guatemala 1
MW - Malawi 1
QA - Qatar 1
SY - Repubblica araba siriana 1
Totale 40.586
Salva come PNG Salva come JPEG
Città #
Beijing 2.850
Chandler 2.564
Dublin 2.041
Ann Arbor 1.263
Houston 1.182
Fairfield 1.171
Villeurbanne 879
Ashburn 832
Singapore 763
Jacksonville 748
Torino 677
Wilmington 672
Medford 666
Princeton 644
Woodbridge 616
Dearborn 584
Seattle 502
Nyköping 472
Warsaw 410
Cambridge 396
Vienna 316
Fremont 278
Pisa 272
Boston 257
Dong Ket 241
Milan 230
Redwood City 191
Düsseldorf 185
Turin 179
San Mateo 178
Nanjing 145
Boardman 132
Toronto 120
New York 113
Frankfurt am Main 110
Guangzhou 107
Santa Clara 107
Verona 107
Hangzhou 84
Shanghai 84
Hefei 83
Norwalk 80
Brussels 79
Hebei 73
San Diego 70
Washington 70
Rome 68
Lachine 58
Munich 52
Tokyo 50
Des Moines 48
Falls Church 48
Wuhan 44
Hong Kong 43
Kunming 41
Mountain View 41
Chongqing 40
Padova 40
Phoenix 39
Jinan 37
San Jose 37
Helsinki 35
Ottawa 35
Zhengzhou 34
Nanchang 32
Chengdu 31
Shenyang 30
Changsha 29
Bologna 28
Seoul 28
Taipei 28
Philadelphia 27
Pune 27
Horia 26
Los Angeles 26
Dallas 24
Brno 23
Fuzhou 23
Central District 22
Napoli 22
Silver Spring 22
Redmond 21
Xian 21
Hyderabad 20
Nürnberg 20
Lappeenranta 19
Tianjin 19
Chennai 18
Nijmegen 18
Paris 18
Piemonte 18
Upper Marlboro 18
Duncan 17
Florence 16
Istanbul 16
Sezze 16
São Paulo 16
Changchun 15
Vestignè 15
Buffalo 14
Totale 25.396
Salva come PNG Salva come JPEG
Nome #
Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy 703
Nuovi inibitori della diidroorotato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide 490
Morgana acts as an oncosuppressor in chronic myeloid leukemia. 432
A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. 408
Comparison of 3 Tfr2-deficient murine models suggestsdistinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues 373
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones 320
A comparative study of myocardial molecular phenotypes of two tfr2β null mice: Role in ischemia/reperfusion 299
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION 297
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 277
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 273
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 269
Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form 233
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 227
Morgana is a new oncosuppressor in CML 226
Non-Oncogene Addiction to BRD in CLL: from JQ1 Response to Resistence 205
Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes 205
Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature 194
Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population 193
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. 192
Analysis of microsatellite instability in chronic lymphoproliferative disorders 187
BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation 185
Early prediction of treatment outcome in acute myeloid leukemia by measurment of WT1 transcript levels in peripheral blood samples collected after chemotherapy 179
THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 178
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH 174
Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis 173
BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia. 172
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034 172
The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias 171
Development of cellular and humoral response against WT1 protein vaccination in mice 170
New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia 169
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 166
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 166
Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. 166
Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse 165
The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy 162
A novel assay to detect calreticulin mutations in myeloproliferative neoplasms 162
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 161
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study 157
Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia 156
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. 152
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 152
Nilotinib in the treatment of chronic myeloid leukemia 152
Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms 149
Role of Cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 148
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily 148
ERYTHROFERRONE EXPRESSION LEVELS IN MYELODYSPLATIC SYNDROMES SHOW CLINICAL RELEVANCE 148
Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection 147
Present results and future perspectives in optimizing chronic myeloid leukemia therapy 146
Deferasirox-dependent iron chelation enhances mitochondrial dysfunction and restores p53 signaling by stabilization of p53 family members in leukemic cells 141
Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1 141
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 140
The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice 137
A new BCR-ABL1 Drosophila model as a powerful tool to elucidate the pathogenesis and progression of chronic myeloid leukemia 136
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice 135
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia 135
Characterization of human mitochondrial ferritin promoter: Identification of transcription factors and evidences of epigenetic control 132
Role of cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 129
DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION 128
Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells 128
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 126
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib 126
Milestones and Monitoring 124
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report 123
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 123
A very sensitive and rapid method for BCR-ABL T315Imutation detection by peptide nucleic acid directed PCR clamping 122
Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex 121
INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY FROM P53 STATUS 118
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR 118
NEW ALTERNATIVE PROTEIN Bcr/Abl-OOF SHOWS ONCOGENIC ACTIVITY BY ACTIVATION OF RAC AND COOPERATION WITH Bcr/Abl IN CHRONIC MYELOID LEUKEMIA. 117
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias 117
A European spectrum of pharmacogenomic biomarkers: Implications for clinical pharmacogenomics 116
A new non canonical role of IkB-alpha in chronic myleoid leukemia pathogenesis 115
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study 114
Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients 113
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 112
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 111
ALTERNATIVE SPLICING VARIANT COULD BE RESPONSIBLE OF MORGANA UNDER-EXPRESSION IN ACML 110
COMPARISON OF DROPLET DIGITAL PCR AND STANDARD PCR IN CHRONIC MYELOID LEUKEMIA PATIENTS IN MR4 110
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase 109
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia 109
Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion. 108
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 107
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 107
A human leukemic T-cell line bears an abnormal and overexpressed c-myc gene: molecular and functional characterization of the rearrangement. 106
Adhesion of polymorphonuclear cells to endothelial cells is physiologically inhibited by Gas6 105
Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study 105
ANALYSIS OF IRON METABOLISM IN TFR2 TARGETED ANIMALS BRAIN 104
TFR2 AND EpoR EXPRESSION AT DIAGNOSIS AS POSSIBLE PREDICTORS OF ERYTHROPOIETIN TREATMENT RESPONSE IN MDS PATIENTS 103
The choice of first-line chronic myelogenous leukemia treatment 102
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 102
Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells 101
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma 100
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion 99
The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta 2-Microglobulin. 99
A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation. 98
Nanocarriers as magic bullets in the treatment of leukemia 98
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 97
4-hydroxynonenal specifically inhibits c-myb but does not affect c-fos expressions in HL-60 cells. 97
A 3' truncation of MYC caused by chromosomal translocation in a human T-cell leukemia increases mRNA stability. 96
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? 96
Totale 16.515
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.112
article - articoli 0
book - libri 0
conference - conferenze 34.348
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.460
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.548 0 0 272 717 429 991 690 462 599 595 418 375
2020/20215.601 453 403 422 328 587 327 490 231 591 396 545 828
2021/20226.174 260 362 277 494 259 230 515 354 225 593 1.153 1.452
2022/20238.161 969 622 220 723 707 2.220 690 480 738 189 392 211
2023/20243.309 462 533 224 166 178 400 107 153 35 202 242 607
2024/2025991 159 690 142 0 0 0 0 0 0 0 0 0
Totale 42.325